StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Xilio Therapeutics's price to book ratio was 0.8× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 0.3× to 6.2×, with a median of 0.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.8×−5.1
2025Oct 31, 20255.8×+3.8
2024Dec 31, 20242.0×+1.7
2023Dec 29, 20230.3×−0.3
2022Dec 30, 20220.6×–

More Xilio Therapeutics figures

See a number that looks wrong?